Upcoming Conference: Catch us as exhibition partners at HTAi Conference 2022, Utrecht, Netherlands
Our multi-disciplinary experts strive to achieve a fine balance of academic quality and industry professionalism.
We provide efficient and innovative HEOR and RWE services tailored to your needs.
We understand your Needs
This is why we focus on maintaining a perfect balance across the three dimensions of academic and professional efficiency.
Timeliness, Quality assurance and Value for money.
ConnectHEOR provides high-quality Health Economics and Outcomes Research (HEOR) and Real World Evidence (RWE) services to generate research-based evidence. We support by demystifying HEOR challenges and efficiently demonstrating a product’s value for internal and external decision making. Check out our services below to know more about our offerings.
Cutting-edge methods to ensure scientifically robust and user-friendly models
RWE & Data Analytics
Analysis of Real World Data to study disease epidemiology and its impact in each phase of product lifecycle
Review & Evidence Synthesis
Assessment of different studies within the scope of existing knowledge for a specific objective
Market access and Value communication
Effectively communicating the clinical and economic value of healthcare technologies to payers and reimbursement agencies
In a small group or personalized one on one session learn HEOR concepts from basic to advanced from the best in industry experts
Although conflicts have existed since the beginning of human civilization, 21st century saw a surge in mass violence, wars, genocide and continued conflict. In 2008 alone, 345 conflicts were ongoing worldwide, of which 134 (39%) involved large-scale violence resulting in millions of deaths.
Antimicrobial Resistance: A threat to the world! But, how does the UK’s ‘Netflix-style’ payment model appeal to roll out new antimicrobials and combat AMR?
This blog covers the latest developments in the Antimicrobial Resistance (AMR) space and how the UK’s recently approved ‘Netflix-style’ subscription-based payment model can work as an example to the world to reverse the decline in the antibiotics category.
No matter how reliable a brand is: from manufacturer to retailer there could be at least 6 different parties (manufacturer, packer, mover, chain of distributors, wholesaler, retailer) who carried your product before it reached you. So is it the right time to change our idea of trust? This is exactly what a blockchain is trying to resolve everywhere. A trust issue.
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia
Saiyed M, Byrnes J, Srivastava T, Scuffham P, Downes M
In the REFLECT trial, lenvatinib showed superior clinical benefits to sorafenib in terms of progression-free survival and was non-inferior for overall survival in the treatment of advanced hepatocellular carcinoma (HCC). The study assessed the cost-effectiveness of lenvatinib compared with sorafenib for patients with advanced HCC in Australia.
Improving Cycle Corrections in Discrete Time Markov Models: A Gaussian Quadrature Approach [Pre Print]
Srivastava T, Strong M, Stevenson MD, Dodd P
In this study, a novel cycle correction method based on Gaussian Quadrature (GQ) is introduced for Markov Models. A simulation study was conducted to compare the GQ method with existing methods. Fifth order GQ method outperformed other existing methods in 99.8% scenarios.
Volume–Outcome Relationships in Open and Endovascular Repair of Abdominal Aortic Aneurysm: Administrative Data 2006–2018
Tong T, Aber A, Chilcott J, Thokala P et al
The aim of this study was to analyse real-world hospital-based patient level data (70k+ patients) to investigate and update volume–outcome relationships after open surgical repair (OSR) and endovascular repair (EVAR) of abdominal aortic aneurysm in England.